{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T10:46:01Z","timestamp":1782470761662,"version":"3.54.5"},"reference-count":27,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.eprac.2026.03.009","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T01:12:05Z","timestamp":1774487525000},"page":"1066-1077","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Effectiveness of Liraglutide versus Dulaglutide in Heart Failure With Preserved Ejection Fraction: A Multicenter Propensity Score\u2013Matched Real-World Study"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8995-1058","authenticated-orcid":false,"given":"Ibrahim","family":"Khalil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Imran","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallab","family":"Sarker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8650-6243","authenticated-orcid":false,"given":"Nabila","family":"Nur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajjad Ghanim","family":"Al-Badri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mst. Mahmuda","family":"Akter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lota","family":"Halder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Turzo","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5681-6522","authenticated-orcid":false,"given":"A.B.M.","family":"Kamrul-Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.eprac.2026.03.009_bib1","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","article-title":"Epidemiology of heart failure with preserved ejection fraction","volume":"14","author":"Dunlay","year":"2017","journal-title":"Nat Rev Cardiol"},{"issue":"9","key":"10.1016\/j.eprac.2026.03.009_bib2","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41569-020-0363-2","article-title":"Evaluation and management of heart failure with preserved ejection fraction","volume":"17","author":"Borlaug","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"16","key":"10.1016\/j.eprac.2026.03.009_bib3","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2026.03.009_bib4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.eprac.2026.03.009_bib5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct Obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.eprac.2026.03.009_bib6","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1161\/CIRCULATIONAHA.119.041886","article-title":"Research priorities for heart failure with preserved ejection fraction: national heart, lung, and blood institute working group summary","volume":"141","author":"Shah","year":"2020","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.eprac.2026.03.009_bib7","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.eprac.2026.03.009_bib8","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.eprac.2026.03.009_bib9","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2026.03.009_bib10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"10193","key":"10.1016\/j.eprac.2026.03.009_bib11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet (London, England)"},{"issue":"7","key":"10.1016\/j.eprac.2026.03.009_bib12","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/dom.12076","article-title":"Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin","volume":"15","author":"Kapitza","year":"2013","journal-title":"Diabetes Obesity Metab"},{"issue":"9951","key":"10.1016\/j.eprac.2026.03.009_bib13","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S0140-6736(14)60976-4","article-title":"Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial","volume":"384","author":"Dungan","year":"2014","journal-title":"Lancet (London, England)"},{"issue":"4","key":"10.1016\/j.eprac.2026.03.009_bib14","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.eprac.2026.03.009_bib15","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2337\/dc17-1114","article-title":"Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: the DUAL VII randomized clinical trial","volume":"41","author":"Billings","year":"2018","journal-title":"Diabetes Care"},{"issue":"21","key":"10.1016\/j.eprac.2026.03.009_bib16","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.eprac.2026.03.009_bib17","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.eprac.2026.03.009_bib18","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.eprac.2026.03.009_bib19","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-Neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.eprac.2026.03.009_bib20","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.eprac.2026.03.009_bib21","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.eprac.2025.06.005","article-title":"Comparative effectiveness of Glucagon-like Peptide-1- receptor agonists in patients with heart failure with preserved or minimally reduced ejection fraction: a comprehensive Bayesian network meta-analysis and network meta-regression","volume":"31","author":"Khalil","year":"2025","journal-title":"Endocr Practice"},{"issue":"4","key":"10.1016\/j.eprac.2026.03.009_bib22","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"issue":"6","key":"10.1016\/j.eprac.2026.03.009_bib23","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE-\/- and LDLr-\/- mice by a mechanism that includes inflammatory pathways","volume":"3","author":"Rakipovski","year":"2018","journal-title":"JACC Basic Transl Sci"},{"issue":"1","key":"10.1016\/j.eprac.2026.03.009_bib24","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/atv.0000615456.97862.30","article-title":"Endothelial GLP-1 (Glucagon-Like Peptide-1) receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension","volume":"40","author":"Helmst\u00e4dter","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.eprac.2026.03.009_bib25","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2337\/dc20-1815","article-title":"HbA1c change and diabetic retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: a meta-analysis and meta-regression","volume":"44","author":"Bethel","year":"2021","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.eprac.2026.03.009_bib26","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/jama.2016.1252","article-title":"Effect of insulin glargine Up-titration vs insulin Degludec\/Liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V randomized clinical trial","volume":"315","author":"Lingvay","year":"2016","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.eprac.2026.03.009_bib27","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.2337\/db14-0976","article-title":"Exenatide protects against Glucose- and lipid-induced endothelial dysfunction: evidence for direct vasodilation effect of GLP-1 receptor agonists in humans","volume":"64","author":"Koska","year":"2015","journal-title":"Diabetes"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26008323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26008323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T09:47:59Z","timestamp":1782467279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26008323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1530891X26008323"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.03.009","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Effectiveness of Liraglutide versus Dulaglutide in Heart Failure With Preserved Ejection Fraction: A Multicenter Propensity Score\u2013Matched Real-World Study","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}